Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Small reduction in quality of life seen with bevacizumab maintenance in patients with ovarian cancer.

Barton MK.

CA Cancer J Clin. 2013 Jul-Aug;63(4):219-20. doi: 10.3322/caac.21189. Epub 2013 Jun 3. No abstract available.

2.

Bevacizumab and ovarian cancer.

Sato S, Itamochi H.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):8-13. doi: 10.1097/GCO.0b013e32834daeed. Review.

PMID:
22123222
3.
4.

[First-line bevacizumab in ovarian cancer].

Mäenpää J.

Duodecim. 2011;127(19):2037-44. Review. Finnish.

PMID:
22073535
5.

Bevacizumab in the treatment of ovarian cancer.

Han ES, Monk BJ.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1339-45. Review.

PMID:
17944559
6.
7.

[Metastatic colorectal carcinoma: bevacizumab extends total survival].

[No authors listed]

Pflege Z. 2013 Apr;66(4):252. German. No abstract available.

PMID:
23634556
8.

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

Teoh D, Secord AA.

Int J Gynecol Cancer. 2012 Mar;22(3):348-59. doi: 10.1097/IGC.0b013e31823c6efd. Review.

PMID:
22266932
9.

Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.

Ikeda Y, Takano M, Oda K, Kouta H, Goto T, Kudoh K, Sasaki N, Kita T, Kikuchi Y.

Int J Gynecol Cancer. 2013 Feb;23(2):355-60. doi: 10.1097/IGC.0b013e31827de69e.

PMID:
23358182
10.

Is it time for some new approaches for treating advanced ovarian cancer?

McGuire WP.

J Natl Cancer Inst. 2006 Aug 2;98(15):1024-6. No abstract available.

PMID:
16882933
11.

Success of bevacizumab trials raises questions for future studies.

Tuma RS.

J Natl Cancer Inst. 2005 Jul 6;97(13):950-1. No abstract available.

PMID:
15998941
12.

Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials.

Ye Q, Chen HL.

Arch Gynecol Obstet. 2013 Sep;288(3):655-66. doi: 10.1007/s00404-013-2820-1. Epub 2013 Mar 31.

PMID:
23543268
13.

[Improving longevity in advanced intestinal cancer].

Schmoll HJ.

Krankenpfl J. 2005;43(1-3):48. German. No abstract available.

PMID:
15912837
14.

Bevacizumab: optimal dose, schedule, and duration of therapy.

Gandara DR, Sangha R, Davies AM.

Clin Lung Cancer. 2007 Nov;8(9):522-3. No abstract available.

PMID:
18186957
15.

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

Richardson DL, Backes FJ, Hurt JD, Seamon LG, Copeland LJ, Fowler JM, Cohn DE, O'Malley DM.

Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10.

PMID:
20382413
16.

Bevacizumab: improved survival at what cost?

Kolesar JM.

Am J Health Syst Pharm. 2005 May 15;62(10):1017. No abstract available.

PMID:
15901584
17.

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.

Eur J Cancer. 2012 Mar;48(4):482-91. doi: 10.1016/j.ejca.2011.12.007. Epub 2012 Jan 16. Review.

PMID:
22257791
18.

Active tuberculosis during temsirolimus and bevacizumab treatment.

Lin CC, Wang JY, Pu YS.

J Clin Oncol. 2013 Jan 10;31(2):e18-20. doi: 10.1200/JCO.2012.43.7566. Epub 2012 Nov 19. No abstract available.

PMID:
23169507
19.

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

Eskens FA, Sleijfer S.

Eur J Cancer. 2008 Nov;44(16):2350-6. doi: 10.1016/j.ejca.2008.07.042. Epub 2008 Sep 11. Review.

PMID:
18789679
20.

Bronchoesophageal fistula and fatal hemoptysis after bevacizumab-containing chemotherapy without radiation in lung cancer.

Schreiber J, Waldburg N.

J Clin Oncol. 2012 Nov 10;30(32):e324. doi: 10.1200/JCO.2012.42.8169. Epub 2012 Sep 24. No abstract available.

PMID:
23008311

Supplemental Content

Support Center